Clinical trials: Respiratory Tract Infection
Covid19
Clinical Study Spartan COVID-19 V2 System (Canada Alternate)
This multicentre prospective study will enroll a sufficient number of patients to afford approximately 30 positives and > 30 negatives (as determined by the SOC - Comparator method) in the United States and/or Canada.
- Trial name
- NCT04628208
- Testing
- Spartan COVID-19 v2 System
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- Spartan Bioscience Inc.
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064415
- Testing
- arformoterol, Salmeterol
- Where
- 90 sites in United States
- Volunteers
- 799 people
- Sponsor
- Sumitomo Pharma America, Inc.
COVID-19
Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients
This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients.
- Trial name
- NCT05675748
- Testing
- Azvudine
- Volunteers
- 400 people
- Sponsor
- Shanghai Henlius Biotech
COVID-19
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.
- Trial name
- NCT05911048
- Testing
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Influenza
Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)
The purpose of this study is to conduct a pilot study to explore the potential use of routinely collected data in General Practitioner (GP) practices to conduct enhanced safety surveillance of seasonal influenza vaccines in the…
- Trial name
- NCT02567721
- Testing
- Vaccine safety surveillance
- Where
- United Kingdom
- Volunteers
- 11,530 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diarrhea, Acute Respiratory Infection
Oral Supplement for Pregnant and Lactating Mothers
To assess protection against early life infections through supplementation of mothers during pregnancy to the newborns' growth, morbidity, immune status intra and extra-uterine.
- Trial name
- NCT01073033
- Testing
- milk supplement 1, milk supplement 2
- Where
- Philippines
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine
This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults, aged from 20 to 55 years old.
- Trial name
- NCT04545749
- Testing
- UB-612
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
Influenza A, Influenza Type B
LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia
The DiaSorin Molecular LIAISON® NES FLU A/B \& COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of…
- Conditions
- Influenza A, Influenza Type B, Coronavirus Disease 2019
- Trial name
- NCT05897515
- Testing
- LIAISON NES FLU A/B & COVID-19
- Where
- Australia
- Volunteers
- 233 people
- Sponsor
- DiaSorin Molecular LLC
Respiratory Syncytial Virus (RSV)
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
- Trial name
- NCT07807449
- Testing
- Recombinant RSV Vaccine (CHO Cell), Adjuvant Suspension, Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Yikang Biotech (Suzhou) Co., Ltd.
Pneumonia, Bacterial
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP).
- Trial name
- NCT02459158
- Testing
- ME1100 inhalation solution
- Where
- 14 sites in United States
- Volunteers
- 25 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
COVID-19
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
This is a phase 1 study to assess the safety and immunogenicity of different formulations of the investigational adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine (SCB-2020S vaccine), when…
- Trial name
- NCT05228314
- Testing
- Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based adjuvant
- Where
- 3 sites in South Africa
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
- Trial name
- NCT04591717
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
COVID-19 Pneumonia, COVID-19
Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above
This is a open label clinical trial to evaluate the efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy people aged 3-17 years old in comparison with healthy population aged 18 years old…
- Trial name
- COVID-19 (NCT04917523)
- Testing
- SARS-CoV-2 Vaccine (Vero Cell), Inactivated
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Community-acquired Pneumonia
Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)
The purpose of this study is to evaluate the safety, tolerability and population pharmacokinetics of oral nemonoxacin in community-acquired pneumonia (CAP) subjects.
- Trial name
- NCT01537250
- Testing
- Nemonoxacin 3 tablets
- Where
- 32 sites in China
- Volunteers
- 192 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Diphtheria, Tetanus
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
The purpose of this study is to evaluate the immune response, safety and reactogenicity after receiving combined DTPa-IPV/Hib vaccine when administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02858440
- Testing
- Infanrix-IPV/Hib
- Where
- 5 sites in Russia
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT02381418
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott
Influenza
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA…
- Trial name
- NCT01147068
- Testing
- 0.5mL Intramuscular Injection
- Where
- 4 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia
A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia
Up to 240 patients with confirmed COVID-19 pneumonia with a baseline imputed PaO2/FiO2 ≤200 receiving oxygen therapy via a high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) will be enrolled at up to 40 sites.
- Trial name
- CARDEA-Plus (NCT05171920)
- Testing
- Auxora
- Where
- 3 sites in United States
- Sponsor
- CalciMedica, Inc.
COVID-19
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization…
- Trial name
- NCT05541289
- Testing
- BBV152
- Where
- United States
- Sponsor
- Ocugen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.